Blood molybdenum level as a marker of cancer risk on BRCA1 carriers.
Milena MatuszczakAdam KiljańczykWojciech MarciniakRóża DerkaczKlaudia StempaPiotr BaszukMarta BryśkiewiczCezary CybulskiTadeusz DębniakGronwald JacekTomasz HuzarskiMarcin LenerAnna JakubowskaSandra PietrzakMarek SzwiecMałgorzata Stawicka-NiełacnaDariusz GodlewskiArtur PrusaczykAndrzej JasiewiczTomasz KluzJoanna Tomiczek-SzwiecEwa Kilar-KobierzyckaMonika SiołekRenata PosmykJoanna Jarkiewicz-TretynRodney ScottSteven NarodJan LubińskiPublished in: Hereditary cancer in clinical practice (2024)
Elevated blood molybdenum levels are associated with an increased risk of ovarian cancer on BRCA1 mutation carriers. Lowering molybdenum levels may potentially reduce cancer risk in this population, and high molybdenum levels could serve as a marker for considering preventive oophorectomy in BRCA1 carriers. Further research is warranted to confirm these findings and explore interventions targeting molybdenum levels as a preventive measure for ovarian cancer in BRCA1 mutation carriers.